In some patients with major depressive disorder (MDD), individual illness characteristics appear consistent with those of a neuroprogressive illness. Features of neuroprogression include poorer symptomatic, treatment and functional outcomes in patients with earlier disease onset and increased number and length of depressive episodes. In such patients, longer and more frequent depressive episodes appear to increase vulnerability for further episodes, precipitating an accelerating and progressive illness course leading to functional decline. Evidence from clinical, biochemical and neuroimaging studies appear to support this model and are informing novel therapeutic approaches. This paper reviews current knowledge of the neuroprogressive processes that may occur in MDD, including structural brain consequences and potential molecular mechanisms including the role of neurotransmitter systems, inflammatory, oxidative and nitrosative stress pathways, neurotrophins and regulation of neurogenesis, cortisol and the hypothalamic–pituitary–adrenal axis modulation, mitochondrial dysfunction and epigenetic and dietary influences. Evidence-based novel treatments informed by this knowledge are discussed.
Although some patients with major depressive disorder (MDD) suffer from only one depressive episode, many display characteristics of a progressive illness. In progressive illness, outcomes1, 2, 3 and treatment efficacy4, 5 are inversely correlated with earlier disease onset and increased number and length of depressive episodes.6 Longer and more frequent depressive episodes appear to increase vulnerability to further relapses,7 facilitating an accelerating and progressive illness course associated with functional decline. For example, the number of past depressive episodes is associated in a dose-dependent manner with memory decline (2–3% per episode; up to 4),1 and increased dementia risk (13% per episode).3 It is probable that depressive episodes cause brain tissue damage and altered physiological functioning through a variety of mechanisms that underpin patient symptomatology and functional decline over time. Evidence from neuroimaging and molecular studies appears to support this model. This understanding is key to informing new treatment strategies. This paper reviews current knowledge of the neuroprogressive processes that may occur in MDD, its structural consequences and molecular basis, and evidence-based novel treatments.
Materials and methods
Data for this review were sourced from electronic databases PUBMED, EMBASE and PsycInfo and were not limited by language or date of publication.
Results and Discussion
Clinical sequelae and structural consequences of MDD
MDD may be associated with stage-related structural brain changes potentially resulting from toxic or adaptive effects produced during depressive episodes. Structural changes are inconsistently found during the first episode; however, they appear more commonly in severe, protracted illness.8 For example, meta-analysis of available data suggests reduced hippocampal volume, a common9, 10, 11, 12, 13 but not universal finding in MDD, is consistently present in patients with illness duration >2 years and in those with >1 depressive episode.9 Hippocampal volume change in MDD is influenced by patient age, gender, illness duration, age of onset, episode frequency, comorbidity, depression subtype and genotype.12 Consistent with trial data,14, 15, 16, 17 a meta-analysis confirmed a direct correlation between increasing episode number and decreased hippocampal volume.18 Length of untreated illness has also been correlated with degree of hippocampal volume reduction,19 although this is not consistently replicated.15 Although some evidence supports early volume reduction (that is, commencing after the first episode)20 not all studies support differential volume reduction in first vs multi-episode patients.21 In fact, most studies including first episode adult patients fail to demonstrate relative volumetric hippocampal changes.20, 22 Correlates of hippocampal atrophy might present themselves in functional consequences of MDD. For example, lower verbal memory scores were associated with decreased hippocampal volumes in patients with recurrent depressive episodes.20 It is important, however, to consider that a number of factors could underpin hippocampal volume change in MDD, including changes in neuronal density, altered fluid content and neuropil.23
Structural alterations in other brain regions including the amygdala,24, 25, 26, 27, 28 orbitofrontal cortex,14, 16, 29 anterior cingulate cortex, basal ganglia and pituitary have been reported in MDD. Most evidence does not support a correlation between MDD characteristics (severity, duration, episode frequency) and volumetric changes in these regions. Exceptions include an inverse correlation between left putamen volume and length of MDD,30 and decreased anterior cingulate cortex volume in currently depressed31, 32 but not euthymic or less depressed patients.33, 34
Biochemical basis of neuroprogression in MDD
Clinical features suggestive of neuroprogression35, 36 have been noted as early as the work of Kraepelin,37 and include increased illness severity over time,38 reduced inter-episode duration as a function of increasing number and length of episodes,39 increasing illness autonomy facilitating spontaneous episodes later in the course7 and underlying genetic risk.7 Two differing pathophysiological models have been utilized to explain these clinical findings; a ‘sensitization model’ and ‘kindling model’.36 Sensitization suggests repeated administration of diverse stimuli causes progressive amplification of neuronal responses over time.40 In this model, psychological or organic stressors causes time-dependent sensitization leading to susceptibility to re-stress that increases progressively.41, 42, 43 The kindling model is based on observations that exogenous substances that induce seizures facilitate brain alterations leading to endogenous seizures in animals. Over time, repeated illness episodes can permanently alter neuronal activity, leading to increased susceptibility to further episodes—akin to the clinical observations of patients with MDD. It is likely these changes are underpinned by altered neuronal gene expression, which could reinforce the maladaptive changes facilitating longer term susceptibility.36
Numerous neurobiological mechanisms contribute to the pathogenesis and neuroprogression of MDD, mediating changes in conjunction with dynamic environmental influences (Figure 1). Major pathways include neurotransmitter systems, inflammatory, oxidative and nitrosative stress (IO&NS), neurotrophins and neurogenesis, cortisol and hypothalamic–pituitary–adrenal axis (HPA) modulation, mitochondrial dysfunction, epigenetic influences and dietary factors (Figure 2).
Pathways to neuroprogression
The serotonergic system is tightly coupled to depression onset,44 stage and neuroprogression. Serotonin (5-hydroxytryptophan (5-HT)) acts as a neurotrophic factor; stimulating neurogenesis and brain-derived neurotrophic factor (BDNF) expression45 that in turn promotes 5-HT neuronal survival. The lowered metabolism of 5-HT in depression may contribute to reduced neurogenesis and subsequent neuroprogression. 5-HT is produced from tryptophan, an essential amino acid catabolized by indoleamine 2,3-dioxygenase (IDO). Cell-mediated immune (CMI) cytokines (for example, interferon gamma (IFN-γ)) can activate IDO leading to tryptophan and 5-HT depletion, and synthesis of tryptophan catabolites (TRYCATs) including kynurenine and quinolinic acid in the plasma and brain. Similarly, some evidence suggests depression is accompanied by IDO activation, lowered plasma tryptophan and relative increases in detrimental TRYCATs and/or decreases in neuroprotective TRYCATs, such as kynurenic acid (for a review, see Maes et al.).46 There are multiple consequences of IDO activation. Reduced tryptophan and 5-HT impairs antioxidant defenses as both are strong antioxidants. Some TRYCATs increase oxidative stress (for example, 5-hydroxyanthranilic acid, 3-hydroxykynurenine, 3-hydroxyanthranilic and quinolinic acid)46 and are involved in processes that facilitate neurodegeneration. TRYCATs, such as kynurenic acid, 3-hydroxyanthranilic acid and/or 3-hydroxykynurenine, impair mitochondrial energy metabolism including adenosine triphosphate production and reduce mitochondrial respiratory mechanisms.47, 48 IFN-γ-induced IDO activity increases synthesis of neurotoxic TRYCATs.46 Quinolinic acid, for example, exerts agonistic effects at N-methyl-D-aspartate receptors a process that leads to excitotoxicity;49 inhibits glutamate uptake;50 and may cause degeneration of nerve cells; hippocampal cell death; destruction of postsynaptic elements; and reduction in central cholinergic functioning.51, 52, 53 All these mechanisms potentially underpin neuroprogression.
Anti-serotonin antibody titers appear significantly higher in MDD patients (54.1%), particularly those with melancholia (82.9%), compared with controls (5.7%).54 Autoimmune responses may interfere with 5-HT neurotransmission, in part helping to explain 5-HT hyporesponsivity in depression,44 which may in turn be involved in lowered neurogenesis and changes in postsynaptic receptor expression and function. Importantly, autoimmune activity directed against 5-HT is significantly associated with the number of previous depressive episodes; patients with >3 depressive episodes had a higher frequency of 5-HT autoimmunity than those with 1 or 2 prior episodes. These findings suggest each depressive episode may progressively increase the propensity to develop autoimmune responses to 5-HT. The latter in turn will increase the risk of new depressive episodes and to sequelae of reduced 5-HT, such as neuroprogression. All in all, the findings show that progressive autoimmune responses against 5-HT contribute to the sensitization or kindling of depression.
Noradrenergic (NA) and dopaminergic (DA) systems
NA alterations are strongly associated with depression. Post-mortem and functional imaging studies reveal altered density and sensitivity of α-2 adrenoreceptors, which modulate noradrenaline release, in prefrontal cortices of depressed suicidal victims.55, 56 Peripheral markers of altered central NA function (decreased platelet α-2 adrenoreceptor density) has also been found in depressed patients.57 Decreased axonal density of NA neurons appears to be induced by IFN-alpha (IFN-α),58 suggesting a potential connection between depressive symptoms and inflammatory mediated effects on the NA system. Antidepressants appear to increase axonal regeneration of cortical NA neurons.59
Alterations in DA function may partially underpin the delayed effects of antidepressants.60 Individuals with MDD have decreased turnover of homovanillic acid, the primary metabolite of dopamine.61, 62 This correlates with a lower DA tone in MDD, a finding consistent with depressogenic effects of DA depletion in depressed patients.63 Greater D-amphetamine responses in patients with MDD are possibly mediated by augmented postsynaptic responses secondary to low basal DA tone.60 Repeated stress may lead to sensitization of the mesolimbic DA system via increased glucocorticoids,64 as glucocorticoids themselves may selectively facilitate DA transmission in the nucleus accumbens.
The role of dopamine in pathogenesis may partially explain incomplete response rates to standard antidepressants,60 reflecting the failure of increased 5-HT and NA neurotransmission to appropriately modify DA signalling. Supporting this, responders to selective serotonin reuptake inhibitors (SSRIs), but not non-responders, exhibit increased dopamine binding to striatal D2 receptors,60 with degree of increased D2 binding correlated with improvement in depressive symptoms.
Inflammation and CMI activation
MDD is characterized by chronic inflammation and CMI activation independent of pathogen response.65, 66 The evidence is underscored by three recent meta-analyses demonstrating increased levels of pro-inflammatory cytokines (PICs) including interleukins (IL-1, IL-6), tumor necrosis factor-alpha (TNF-α)67, 68 and T-cell activation indicated by increased serum levels of soluble IL-2 receptors69 in MDD. Another consistent finding is increased neopterin, indicating increased IFN-γ-mediated macrophage activation.66 Increased production of PICs and CMI-related cytokines (for example, IFN-γ, IL-2) elicits depressive- and anxiety-like behaviors,70 with even small concentration changes consistently associated with the cardinal symptoms of depression. Moderate increments in cytokine levels may cause depression in individuals vulnerable to inflammatory changes (for example, patients receiving hemodialysis or IFN-α-based immunotherapy, post-partum women).71 Vulnerability to inflammatory triggers in depression is determined by factors including decreased levels of immunologically active peptidases (dipeptidylpeptidase IV and prolylendopeptidase) and by polymorphisms in cytokine and oxidative and nitrosative stress (O&NS) genes.70
Changes in inflammatory markers appear related to the number of depressive episodes. Neopterin is significantly increased in patients with ⩾2 depressive episodes compared with those with ⩽1 episode,72 and neopterin, IL-1 and TNF-α are significantly higher in patients with ⩾3 depressive episodes.73 These findings suggest prior depressive episodes sensitize PIC responses and IFN-γ-induced mechanisms, potentially increasing vulnerability for further depressive episodes. Additionally, patients with a lifetime history of MDD showed increased IL-6 and soluble IL-1 receptor antagonist (indicating monocytic activation) in the early puerperium, suggesting prior depression sensitizes inflammatory responses.74 PICs and IFN-γ-related mechanisms mediate central sensitization in behavioral responses to maternal separation75 and may at least partially mediate the above sensitization.
Increased levels of PICs and CMI-related cytokines may contribute to neuroprogression.76 Increased IFN-γ production stimulates IDO and increases production of neurotoxic TRYCATs. Moreover, IFN-γ sensitizes cortical and cerebellar neurons to neurotoxic peptides, increases neuronal death, participates in neuronal loss and exacerbates neurotoxicity in neurodegenerative disorders.77, 78 IL-2 potentiates the effects of N-methyl-D-aspartate and has a role in reactive astrogliosis, myelin damage and neuronal loss in many brain regions.79, 80 IL-1β has neurotoxic effects on astrocytes and endothelial cells, thereby causing increased production of free radicals and metaloproteinases, which together may cause neuronal death, and exacerbates cell death by increasing seizure activity and N-methyl-D-aspartate receptor functions.81, 82, 83, 84, 85 Moreover, increased IL-1 production impairs hippocampal neurogenesis and cytogenesis; reduces BDNF expressions at both the messenger ribonucleic acid and protein level; reduces neurotrophin TrK receptor expression in the hippocampus and increases p75 receptor expression, subsequently impairing neuronal survival.86, 87, 88
TNF-α influences neuroprogressive processes such as silencing of cell survival signals, activation of caspase-dependent mechanisms and potentiation of glutamate neurotoxicity.89 Neopterin, in turn, potentiates the effects of reactive oxygen species (ROS), such as hydrogen peroxide.90, 91 Neopterin also triggers inducible nitric oxide synthase gene expression enhancing nitric oxide (NO) production.92 Therefore, neopterin may have a role in activating O&NS pathways observed in depression.93 Moreover, neopterin may elicit programmed cell death caused by PICs and O&NS.92, 94
Taken together, inflammation and CMI activation may contribute to the staging or recurrence of MDD. Exposure to previous depressive episodes magnifies the responses of depressogenic cytokines, potentially increasing the likelihood of new depressive episodes. These PICs, CMI-related cytokines and compounds such as neopterin induce neuroprogressive processes facilitate staging of depression.
Corticotrophin-releasing hormone (CRH) and the HPA axis
Numerous lines of evidence support a role of CRH and HPA axis alteration in MDD (for a review, see Swaab et al.).95 Many depressive symptoms can be induced by intracerebroventricular injections of CRH,96 and patients with MDD exhibit higher CRH neuronal activation and raised salivary, plasma and urinary cortisol compared with aged matched controls.97 It is postulated that HPA axis hyperactivity may result from early life programming.98 Events that sensitize the HPA axis in utero including maternal stress or smoking, and early bereavement or abuse in childhood lead to a higher risk of developing MDD later in life. An enduring sensitivity of CRH neurons is commonly seen in depressed individuals, and may reflect a state of glucocorticoid resistance, which facilitates increased exposure to glucocorticoids throughout the brain and body.99 Chronic use of antidepressants upregulate glucocorticoid receptor (GR) expression and function, leading to increased negative feedback and subsequent decreases in HPA axis reactivity.100 In addition, the GR has a key role in mediating antidepressant-induced hippocampal neurogenesis.101 Alteration of action appears to include inhibitory effects on cell membrane steroid transporters (for example, P-glycoprotein), leading to decreased glucocorticoid expulsion and higher intracellular concentrations (increasing GR function), and activation of GR translocation from cytoplasm to the nucleus, decreasing GR expression and function.100
The HPA axis is activated by PICs involved in depression and neuroprogression, including IL-6, TNFα, IL-1β and IFN-γ.102, 103 Maes et al.104 showed that HPA axis hyperactivity, either increased baseline activity or glucocorticoid resistance, is associated with increased production of PICs. There is evidence that glucocorticoid resistance in depression is caused by IL-2 and IL-1β-related mechanisms.105 The increased production of PICs and CMI-related cytokines could thus induce HPA axis hyperactivity by causing glucocorticoid resistance and increased baseline hormonal activity.98, 104, 105, 106
Changes in gene expression may additionally underlie environmentally mediated HPA axis hyperactivity susceptibility. Patients suffering from MDD or bipolar depression have been demonstrated to exhibit decreased GR messenger ribonucleic acid levels in the frontal cortex, amygdala and hippocampus.107, 108 Polymorphisms (rs6198, rs6191 and rs33388) of the nuclear receptor subfamily 3, group C, member 1 gene (which codes for the GR) and FK506 binding protein 5 (FKBP5) gene are associated in mediating environmentally induced onset of depressive risk.109, 110 FKBP5, which is found in both the cytoplasm nucleus,111 is a co-chaperone of heat shock protein 90 that modulates GR sensitivity. Increased expression of FKBP5, through gene polymorphism-induced upregulation, appears related to increased GR resistance. FKBP5 binding lowers GR affinity for cortisol, reducing negative feedback and its expression is actually induced by steroids. In this respect, increased environmental stressors, facilitating increased glucocorticoid expression, may induce FKBP5 expression and further GR resistance (for a review, see Binder),112 which may increase risk for MDD.
O&NS and mitochondrial dysfunctions
Oxidative stress: Inflammatory and mitochondrial processes can increase production of ROS and reactive nitrogen species (RNS) including superoxide, NO, peroxynitrite and peroxides. Under normal conditions, the potentially damaging effects of increased ROS and RNS on lipids, proteins, deoxyribonucleic acid (DNA) and mitochondria are counterbalanced by defense systems, including antioxidants and antioxidant enzymes. Activation of O&NS pathways occurs when excess of ROS/RNS and/or compromised antioxidant defenses are present. Beside damage to fatty acids, proteins, DNA and mitochondria, damage by O&NS may initiate autoimmune responses. Thus, oxidative stress may damage fatty acids that in turn cause lipid peroxidation and damage to cell membranes. Increased production of NO and peroxynitrite may cause nitration and nitrosylation of proteins. These O&NS processes alter the chemical structure of endogenous fatty acids and proteins, potentially rendering them immunogenic, inducing immunoglobulin-mediated autoimmune responses directed against fatty acid and protein neoepitopes.
MDD is accompanied by lowered antioxidant levels, including coenzyme Q10, vitamin E, zinc, glutathione; and reduced antioxidant enzyme activities, such as glutathione peroxidase (for a review, see Maes et al.).113 Increased O&NS damage is indicated by signs of lipid peroxidation, including increased plasma levels of malondialdehyde, a by-product of polyunsaturated fatty acid (PUFA) peroxidation, arachidonic acid and increased 4-hydroxynonenal expression in the anterior cingulate cortex of bipolar patients (for a review, see Maes et al.).113 Damage to DNA is indicated by increased levels of 8-hydroxy-2-deoxyguanosine, a mutagenic DNA lesion, in the urine or plasma of depressed patients. There is also evidence for immunoglobulin-G and immunoglobulin-M mediated autoimmune responses against neoepitopes including oxidized low-density lipoprotein, the three major anchorage molecules (palmitic and myristic acid, and S-farnesyl-L-cysteine) and NO-adducts, including NO-phenylalanine and NO-tyrosine.113
Damage by O&NS and subsequent autoimmune responses are major causes of disease progression, as demonstrated by the contributory roles of lipid peroxidation and oxidative damage to proteins in neurodegenerative disorders.114, 115, 116 Pathophysiological mechanisms include activation of the Janus kinase/signal transducer and activator of transcription pathway (influencing DNA transcription) in glia and astroglia, lowered expression of neurofilaments, reduced neuronal viability and increased cell necrosis via mitochondrial dysfunction, membrane destabilization and ion dysregulation.117, 118, 119 Moreover, lipid peroxidation products exert specific neuroprogressive effects.
For example, malondialdehyde inhibits the nucleotide excision repair system, sensitizing mutagenesis and damaging DNA,120 and causes mitochondrial damage by increasing mitochondrial ROS, inhibiting mitochondrial respiratory processes and reducing the mitochondrial membrane potential and mitochondrial antioxidant levels.121 4-Hydroxynonenal induces inflammation and neuronal cell death via apoptotic pathways, leads to accumulation of peroxides in astrocytes, impairments in axon regeneration, aberrant axonal functioning, loss of active mitochondria and suppressed mitochondrial respiration.122, 123, 124, 125, 126
The immunoglobulin-M mediated autoimmune responses in depression not only amplify inflammatory reactions but target molecules involved in cell signalling pathways. The three major anchorage molecules (palmitic acid, myristic acid and S-farnesyl-L-cysteine) bind hundreds of functional proteins and receptors to the inner cell membrane, determining proper functioning of these proteins and receptors. Palmitoylation, myristoylation and farnesylation are therefore required for intracelluar signal transduction, cellular architecture, cellular differentiation, DNA synthesis and cell growth.127, 128, 129
Autoimmune responses targeting the three anchorage molecules and other key components may lead to aberrations in cell signaling functions in depression. Further, these findings demonstrate autoimmune responses directed against functionally active neo-epitopes confer increased risk to developing chronic depression, as autoimmune processes amplify inflammatory reactions and interfere with critical cell signaling pathways that activate disease pathways involved in the pathophysiology of chronic depression.
NO production and nitrosative stress: Disturbed NO production appears related to the pathogenesis of depression.130, 131, 132 Endogenous hippocampal NO production is associated with the pathophysiology of MDD,133, 134 and agents that block NOS can produce antidepressant effects. SSRIs (for example, paroxetine) have been demonstrated to act as a NOS inhibitors, and the NO inhibitor methylene blue has putative antidepressant effects.135
NO has roles in immune, neuronal, paracrine and endocrine regulation, and exerts influences over numerous neurotransmitter systems. NO may inhibit the basal and potassium-stimulated release of NA136 and potentially inhibits reuptake of noradrenaline by influencing cyclic guanosine monophosphate (cGMP)-mediated uptake processes.137
Inhibition of NOS decreases 5-HT turnover in the frontal cortex138 and fluoxetine down regulates hippocampal NOS139 and striatal NO production.140 Activation of 5-HT1a receptors appears inversely related to NOS expression.139 NO also influences DA transmission134 and interacts with the excitatory glutamatergic system. Animal models suggest NO, via altering the level of cGMP, can produce depression-like states.141 cGMP is metabolized via phosphodiesterase enzymes, and drugs that affect the phosphodiesterase enzyme cGMP functions may be useful in MDD.142 In addition, N-1-acetyl-5-methoxylkyuramine, a brain metabolite of melatonin, inhibits NOS,143 which is consistent with an antidepressant function of melatonin receptor-1 and melatonin receptor-2 melatonergic receptor agonist agomelatine.144
The increased immunoglobulin-M mediated immune responses directed against NO-adducts indicate increased nitrosylation and chronically elevated NO levels in depression.93 The conversion of organic compounds into nitroso derivatives (NO-formation) provides an index of ROS and RNS production. Results suggest increased ROS and RNS enables nitrosation of proteins facilitating autoimmune responses against these nitrosated neo-epitopes (nitrosyls).
Mitochondrial dysfunction: MDD is associated with decreased brain energy generation.145 Dysfunctional mitochondrial energy production is associated with depression146, 147, 148, 149, 150 and may contribute to pathogenesis through influencing neurogenesis and cell survival.151 Stress induces robust inhibition of mitochondrial energy generation152 and damages mitochondrial ultrastructure. Changes in mitochondrial size, distribution and function are observed in MDD.153 Antidepressants and lithium upregulate mitochondrial energy generation,154 and N-acetylcysteine (NAC) enhanced mitochondrial function and cognition in an animal model of mitochondrial dysfunction.4 Mitochondrial dysfunction impairs neural progenitor cell function155 and can result from action of various inflammatory mediators including TNF-α, IL-6 and ROS.151 TNF-α suppresses pyruvate dehydrogenase156 and mitochondrial complexes I and IV.157
As the high metabolic rate of the brain strongly depends on mitochondrial adenosine triphosphate production, dysfunctional mitochondria have a key role in neurodegenerative disorders.158 Dysfunctional mitochondria together with the IO&NS pathways synergistically contribute to the neurodegenerative processes in Parkinson's disease, Alzheimer's dementia, Huntington's disorder and amyotrophic lateral sclerosis.159, 160 Mitochondrial-derived hyperproduction of ROS and the mitochondrial apoptotic pathway controlling caspase-9 and release of cytochrome c are critical in the neurodegenerative processes.
Neurotrophins and neurogenesis
The importance of neurogenesis for hippocampal function161 is supported by the high rate of ongoing neuronal generation in the dentate gyrus.162 Neurotrophins are key mediators of normal neurogenesis, and numerous findings support the role of neurotrophins and neurogenesis in MDD. In animal models, stress reduces neurogenesis in the subgranular zone of the dentate gyrus and the subventricular zone of the lateral ventricle, potentially resulting in neuronal atrophy, neurotoxicity and increased vulnerability to insults. This hippocampal damage appears driven by increased glucocorticoids, although 5-HT, N-methyl-D-aspartate and neurotrophins are also implicated. Glucocorticoids have a role in allostatic regulation function, modulating the potentially noxious effects of excitatory amino-acid neurotransmitters in response to environmental changes as well as impacting neuronal excitability involved in learning and memory.
Neurotrophins regulate neurogenesis in the hippocampus, and affect cell survival via inhibition of apoptotic pathways. MDD is characterized by altered levels of neurotrophins BDNF,163 vascular endothelial growth factor,164 insulin growth factor,165, 166 fibroblast growth factors,167 S100 calcium-binding protein B (s100b),168 B-cell lymphoma 2 and glial cell line-derived neurotrophic factor.169 Administration of these factors produces antidepressant effects in animal models,170, 171 and traditional antidepressant medications may alter neurotrophin levels.172
Decreased BDNF appears correlated with severity and recurrent MDD,173, 174, 175 although this was not replicated in a recent study.176 Molendijk et al.176 demonstrated normalization of BNDF lags symptomatic improvement, noting that a wide variety of factors influence BDNF levels. BDNF concentration appears to be lower in untreated depressed patients compared with those on antidepressant therapy,173 but the effect of increasing BDNF appears mostly related to 5-HT modulation.176 Neurogenesis appears increased by treatment with antidepressant drugs as well as electroconvulsive therapy, although this may also be explained by mistaking induced dematurated granule cells for new neurons.161
Exposure to neonatal stress can lead to decreased levels of hippocampal BDNF177, 178 through altered gene expression. Altered BDNF expression may produce disease vulnerability as consequence of a smaller neuronal reserve and decreased neuronal survival.179 Besides the hippocampus, altered levels of BDNF and the TRkB receptors to which they bind may occur in DA pathways projecting from the ventral tegmental area in the midbrain to the nucleus accumbens.36, 180 Progressively decreasing BDNF expression may underpin the larger alterations in brain region volume associated with an increased number of depressive episodes.9, 181 Such a possibility would fit with a neuroprogressive model of MDD.
Other neurotrophins appear to experience greater derangement with increasing episode frequency. For example, levels of S100B, a calcium-binding protein that exerts a variety of neurotrophic and neurotoxic effects, are higher in patients with recurrent MDD compared with first episode or controls.168 S100B exerts complicated effects at both an intracellular and extracellular level, and is known to be potentially toxic at higher concentrations through activation of the receptor for advanced glycation end product.182
Inhibition of neurogenesis appears to block the effects of antidepressants, although it does not necessarily produce depression-like behavior or increase sensitivity to chronic stress. An additional caveat is that the effects of chronic stress and antidepressants on depression models seem more tightly correlated the density of the dendritic arbor of pyramidal and granule cells than with neurogenesis. For this reason, the relationship between hippocampal neurogenesis and MDD requires further elucidation, although perturbations in the degree of neurogenesis does appear to be critically related to MDD pathogenesis.161
Epigenetic modification of gene function may be related to MDD pathogenesis183 although this is a nascent field. Levels of methylation of genes associated with depression, including nuclear receptor subfamily 3, group C, member 1 and 5-HTTLPR (serotonin transporter-linked polymorphic region) may be altered by early life events and might be amenable to pharmacological intervention.184, 185, 186 Recently, chronic administration of escitalopram normalized methylation of the P11 gene in a rodent model of depression leading to increased P11 expression.187 Potential inter-relationships exist between modulation of gene methylation and inflammatory processes in pathogenesis of depression,183 including alterations in activities related to tryptophan metabolism. Modification of the epigenetic profile of neuronal DNA is gaining recognition as a mechanism for activity-dependent epigenetic regulation in the adult nervous system.188 Necessarily, studies in humans often focus on epigenetic changes in peripheral tissues as biomarkers, which may or may not be representative of epigenetic changes in neuronal cells. Epigenetics provides a mechanism for environmental stressors to impact on gene expression and exploration of epigenetic influences presents an appealing approach to explain MDD neuropathogenesis, although the currently available empirical data has numerous limitations.
Neuroprotection and antidepressants
Antidepressants influence pathways involved in MDD neuroprogression. As previously mentioned, antidepressants may modulate neurotrophin levels including BDNF.189, 190, 191 Antidepressants interact directly with the TrkB receptor192 independent of BDNF or monoamine neurotransmitters193 systems, potentially through alternative pathways including ion channel regulation, Sigma-1 receptors and adenosine reuptake protein modulation. Interestingly, antidepressant activation of TrkB does not occur in vitro (for example, in isolated cell lines), suggesting an in context network may underpin this effect.193 Given this, agents that interact directly with TrkB194 are being developed, with early findings suggesting potential antidepressant and anxiolytic properties.195, 196
Antidepressants exert anti-inflammatory properties, potentially through modulating levels of pro and anti-inflammatory cytokines. For example, the initially increased levels of CMI cytokines and PICs (for example, IL-12, IFN-γ) are decreased by SSRIs. In addition, SSRIs increase anti-inflammatory cytokine (for example, IL-10, IL-4, transforming growth factor-β1) levels in depressed patients.197, 198 Other non-SSRI antidepressants appear to modulate levels of inflammatory cytokines199, 200 leading to an anti-inflammatory effect. For example, the tricyclic desipramine may decrease neuronal production of TNF-α, an effect that over time alters NA transmission,201 potentially by modifying expression or function of α2-adrenergic receptors
New therapeutic targets
Anti-inflammatory agents may be beneficial in MDD.202 Acetylsalicylic acid (aspirin) augments ROS reduction when combined with fluoxetine,203 and has demonstrated faster antidepressant effects in combination than fluoxetine alone in animal models204 and an open-label clinical study.205 Aspirin augmentation may be have particular potential in treatment-resistant populations.206 Celecoxib, a COX-2 inhibitor, has demonstrated benefit in reducing depressive symptoms in randomized placebo-controlled trials when combined with reboxetine207 and fluoxetine.208 Similarly, the tetracylic antibiotic agent minocycline, which enhances neurogenesis and exhibits strong anti-inflammatory effects,209 appears to augment antidepressant effects of desipramine in rat behavior,210 although few other trial data exist.211 Erythropoietin, which shows neuroprotective and neurotrophic properties in hypoxic-ischemic, traumatic, excitotoxic and inflammatory models, appears to be effective in animal as well as proof-of-concept human depression studies.212
The role of specific PIC antagonists has also been explored in special populations. For example, TNF-α antagonists etanercept and infliximab may improve depressive symptoms in patients suffering from psoriasis.213, 214 Agents that induce release of PICs such as IFN-α, used in treatment of viral illness's including hepatitis C, can induce MDD symptoms;215, 216 this may be prevented by pre-administration of SSRIs.217
Statins impact regulation of IO&NS. Statins had anti-IO&NS effects in a model of spontaneously hypertensive rats218 and in patients with hypertension and dyslipidemia.219 Following an acute cardiac event, statins were associated with reductions of TNF-α and IFN-γ generation in stimulated T-lymphocytes.220 Statins also upregulate glutathione synthesis,221 decrease lipid peroxidation222 and reduce oxidized low-density lipoprotein accumulation, potentially through stimulating superoxide dismutase 1, a free radical scavenging enzyme. Clinical studies suggest statins may reduce the risk of depression in at risk populations,223, 224 which may be ascribed to their anti-IO&NS effects, and may be a promising therapeutic avenue.224, 225
Diet, including PUFAs
Certain dietary measures and regular physical activity are associated with reduced depressive symptoms that may be partially mediated through regulation of IO&NS. Poorer quality diets (characterized by large proportion of processed foods high in fat and sugars) are associated with increased likelihood of depression.226 Consumption of such highly palatable foods potentially mediates increased ROS227 and inflammatory cytokines. Certain dietary items such as PUFAs, zinc, selenium and magnesium appear to exhibit anti-inflammatory properties and are potential therapeutic modalities. Deprivation of omega-3 PUFAs increased depressive symptoms in a rat model, and supplementation can exert antidepressant-like effects.228, 229, 230, 231 Omega-3 PUFAs exert anti-inflammatory effects88 in both animals232, 233 and humans,234 although data in depressed populations are limited. In addition, Omega-3 is positively associated with grey matter volume and deficiency impairs astrocyte-mediated neuron-vascular coupling.235, 236 Supplemental omega-3 PUFAs appear to be effective for depressive symptoms, but study heterogeneity is limiting.237, 238
Specific antioxidants may exert antidepressant effects. NAC augmentation improved depressive symptoms in bipolar disorder,239 and administration of NAC decreases immobility time in depression models of male Wistar rats.240 NAC is a potent antioxidant that increases glutathione241 and that additionally has anti-inflammatory effects, promotes neurogenesis and neuronal survival, and reverses models of mitochondrial toxicity.239, 242, 243 These findings are corroborated by studies on the effects of ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one), a compound that mimics the antioxidant and neuroprotective activity of glutathione peroxidase.244, 245 Similar to NAC, ebselen also yields antidepressant effects246 and prevents the activation induction of IO&NS pathways that accompany immobilization stress.247
MDD is a complex disorder. Understanding pathways aiding pathogenesis and neuroprogression provides opportunities for improving treatment outcomes. Emphasis on relapse prevention is supported by the concept of MDD as a neuroprogressive disorder with each episode precipitating increased functional impairment and sensitivity for further episodes. It is, however, necessary to emphasize the bidirectional nature of the process, and that substantial plasticity and remodelling can occur. A number of potential novel treatment pathways are emerging out of the rapidly expanding research base.
Gorwood P, Corruble E, Falissard B, Goodwin GM . Toxic effects of depression on brain function: impairment of delayed recall and the cumulative length of depressive disorder in a large sample of depressed outpatients. Am J Psychiatry 2008; 165: 731–739.
Ormel J, Oldehinkel AJ, Nolen WA, Vollebergh W . Psychosocial disability before, during, and after a major depressive episode: a 3-wave population-based study of state, scar, and trait effects. Arch Gen Psychiatry 2004; 61: 387–392.
Kessing LV, Andersen PK . Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry 2004; 75: 1662–1666.
Tominaga K, Okazaki M, Higuchi H, Utagawa I, Nakamura E, Yamaguchi N . Symptom predictors of response to electroconvulsive therapy in older patients with treatment-resistant depression. Int J Gen Med 2011; 4: 515–519.
Okuda A, Suzuki T, Kishi T, Yamanouchi Y, Umeda K, Haitoh H et al. Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder. Psychiatry Clin Neurosci 2010; 64: 268–273.
Kendler KS, Thornton LM, Gardner CO . Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the ‘kindling’ hypothesis. Am J Psychiatry 2000; 157: 1243–1251.
Kendler KS, Thornton LM, Gardner CO . Genetic risk, number of previous depressive episodes, and stressful life events in predicting onset of major depression. Am J Psychiatry 2001; 158: 582–586.
Lorenzetti V, Allen NB, Fornito A, Yucel M . Structural brain abnormalities in major depressive disorder: a selective review of recent MRI studies. J Affect Disord 2009; 117: 1–17.
McKinnon MC, Yucel K, Nazarov A, MacQueen GM . A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci 2009; 34: 41–54.
Campbell S, Marriott M, Nahmias C, MacQueen GM . Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry 2004; 161: 598–607.
Caetano SC, Hatch JP, Brambilla P, Sassi RB, Nicoletti M, Mallinger AG et al. Anatomical MRI study of hippocampus and amygdala in patients with current and remitted major depression. Psychiatry Res 2004; 132: 141–147.
Eker C, Gonul AS . Volumetric MRI studies of the hippocampus in major depressive disorder: meanings of inconsistency and directions for future research. World J Biol Psychiatry 2010; 11: 19–35.
Malykhin NV, Carter R, Seres P, Coupland NJ . Structural changes in the hippocampus in major depressive disorder: contributions of disease and treatment. J Psychiatry Neurosci 2010; 35: 337–343.
Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS . Hippocampal volume reduction in major depression. Am J Psychiatry 2000; 157: 115–118.
Frodl T, Meisenzahl EM, Zetzsche T, Hohne T, Banac S, Schorr C et al. Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. J Clin Psychiatry 2004; 65: 492–499.
Frodl T, Meisenzahl EM, Zill P, Baghai T, Rujescu D, Leinsinger G et al. Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression. Arch Gen Psychiatry 2004; 61: 177–183.
Frodl T, Schaub A, Banac S, Charypar M, Jager M, Kummler P et al. Reduced hippocampal volume correlates with executive dysfunctioning in major depression. J Psychiatry Neurosci 2006; 31: 316–323.
Videbech P, Ravnkilde B . Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry 2004; 161: 1957–1966.
Sheline YI, Gado MH, Kraemer HC . Untreated depression and hippocampal volume loss. Am J Psychiatry 2003; 160: 1516–1518.
MacQueen GM, Campbell S, McEwen BS, Macdonald K, Amano S, Joffe RT et al. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci USA 2003; 100: 1387–1392.
Vythilingam M, Vermetten E, Anderson GM, Luckenbaugh D, Anderson ER, Snow J et al. Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. Biol Psychiatry 2004; 56: 101–112.
Inagaki M, Matsuoka Y, Sugahara Y, Nakano T, Akechi T, Fujimori M et al. Hippocampal volume and first major depressive episode after cancer diagnosis in breast cancer survivors. Am J Psychiatry 2004; 161: 2263–2270.
Stockmeier CA, Mahajan GJ, Konick LC, Overholser JC, Jurjus GJ, Meltzer HY et al. Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry 2004; 56: 640–650.
Sheline YI, Gado MH, Price JL . Amygdala core nuclei volumes are decreased in recurrent major depression. Neuroreport 1998; 9: 2023–2028.
Kronenberg G, Tebartz van Elst L, Regen F, Deuschle M, Heuser I, Colla M . Reduced amygdala volume in newly admitted psychiatric in-patients with unipolar major depression. J Psychiatr Res 2009; 43: 1112–1117.
Frodl T, Meisenzahl E, Zetzsche T, Bottlender R, Born C, Groll C et al. Enlargement of the amygdala in patients with a first episode of major depression. Biol Psychiatry 2002; 51: 708–714.
Frodl T, Meisenzahl EM, Zetzsche T, Born C, Jager M, Groll C et al. Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects. Biol Psychiatry 2003; 53: 338–344.
Hajek T, Kopecek M, Kozeny J, Gunde E, Alda M, Hoschl C . Amygdala volumes in mood disorders--meta-analysis of magnetic resonance volumetry studies. J Affect Disord 2009; 115: 395–410.
Monkul ES, Hatch JP, Nicoletti MA, Spence S, Brambilla P, Lacerda AL et al. Fronto-limbic brain structures in suicidal and non-suicidal female patients with major depressive disorder. Mol Psychiatry 2007; 12: 360–366.
Lacerda AL, Nicoletti MA, Brambilla P, Sassi RB, Mallinger AG, Frank E et al. Anatomical MRI study of basal ganglia in major depressive disorder. Psychiatry Res 2003; 124: 129–140.
Caetano SC, Kaur S, Brambilla P, Nicoletti M, Hatch JP, Sassi RB et al. Smaller cingulate volumes in unipolar depressed patients. Biol Psychiatry 2006; 59: 702–706.
Botteron KN, Raichle ME, Drevets WC, Heath AC, Todd RD . Volumetric reduction in left subgenual prefrontal cortex in early onset depression. Biol Psychiatry 2002; 51: 342–344.
Bremner JD, Vythilingam M, Vermetten E, Nazeer A, Adil J, Khan S et al. Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry 2002; 51: 273–279.
Brambilla P, Nicoletti MA, Harenski K, Sassi RB, Mallinger AG, Frank E et al. Anatomical MRI study of subgenual prefrontal cortex in bipolar and unipolar subjects. Neuropsychopharmacology 2002; 27: 792–799.
Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35: 804–817.
Post RM . Mechanisms of illness progression in the recurrent affective disorders. Neurotox Res 2010; 18: 256–271.
Kraepelin E . Manic depressive insanity and paranoia. J Nervous Mental Disease 1921; 53: 350.
Kessing LV . Severity of depressive episodes during the course of depressive disorder. Br J PsychiatryJ Mental Sci 2008; 192: 290–293.
Kessing LV . Recurrence in affective disorder. II. Effect of age and gender. Br J Psychiatry J Mental Sci 1998; 172: 29–34.
Bell IR, Hardin EE, Baldwin CM, Schwartz GE . Increased limbic system symptomatology and sensitizability of young adults with chemical and noise sensitivities. Environ Res 1995; 70: 84–97.
Antelman SM, Levine J, Gershon S . Time-dependent sensitization: the odyssey of a scientific heresy from the laboratory to the door of the clinic. Mol Psychiatry 2000; 5: 350–356.
Bell IR . White paper: neuropsychiatric aspects of sensitivity to low-level chemicals: a neural sensitization model. Toxicol Ind Health 1994; 10: 277–312.
Antelman SM, Caggiula AR, Kocan D, Knopf S, Meyer D, Edwards DJ et al. One experience with ‘lower’ or ‘higher’ intensity stressors, respectively enhances or diminishes responsiveness to haloperidol weeks later: implications for understanding drug variability. Brain Res 1991; 566: 276–283.
Maes M, Meltzer HY . The serotonin hypothesis of major depression. In: Bloom F, Kupfer D (eds). Psychopharmacology, the Fourth Generation of Progress. Raven Press: New York, 1995, pp 933–944.
Djavadian RL . Serotonin and neurogenesis in the hippocampal dentate gyrus of adult mammals. Acta Neurobiol Exp (Wars) 2004; 64: 189–200.
Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R . The new ‘5-HT’ hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 702–721.
Schuck PF, Tonin A, da Costa Ferreira G, Viegas CM, Latini A, Duval Wannmacher CM et al. Kynurenines impair energy metabolism in rat cerebral cortex. Cell Mol Neurobiol 2007; 27: 147–160.
Baran H, Staniek K, Kepplinger B, Stur J, Draxler M, Nohl H . Kynurenines and the respiratory parameters on rat heart mitochondria. Life Sci 2003; 72: 1103–1115.
Schwarcz R, Whetsell Jr WO, Mangano RM . Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983; 219: 316–318.
Tavares RG, Tasca CI, Santos CE, Alves LB, Porciuncula LO, Emanuelli T et al. Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem Int 2002; 40: 621–627.
Khaspekov L, Kida E, Victorov I, Mossakowski MJ . Neurotoxic effect induced by quinolinic acid in dissociated cell culture of mouse hippocampus. J Neurosci Res 1989; 22: 150–157.
Garthwaite G, Garthwaite J . Quinolinate mimics neurotoxic actions of N-methyl-D-aspartate in rat cerebellar slices. Neurosci Lett 1987; 79: 35–39.
Levivier M, Przedborski S . Quinolinic acid-induced lesions of the rat striatum: quantitative autoradiographic binding assessment. Neurol Res 1998; 20: 46–56.
Maes M, Ringel K, Kubera M, Berk M, Rybakowski JK . Increased autoimmune activity against 5-HT: a key component of 3 depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. J Affect Disord 2012; 136: 386–392.
Escriba PV, Ozaita A, Garcia-Sevilla JA . Increased mRNA expression of alpha2A-adrenoceptors, serotonin receptors and mu-opioid receptors in the brains of suicide victims. Neuropsychopharmacology 2004; 29: 1512–1521.
Ordway GA, Schenk J, Stockmeier CA, May W, Klimek V . Elevated agonist binding to alpha2-adrenoceptors in the locus coeruleus in major depression. Biol Psychiatry 2003; 53: 315–323.
Maes M, Van Gastel A, Delmeire L, Meltzer HY . Decreased platelet alpha-2 adrenoceptor density in major depression: effects of tricyclic antidepressants and fluoxetine. Biol Psychiatry 1999; 45: 278–284.
Ishikawa J, Ishikawa A, Nakamura S . Interferon-alpha reduces the density of monoaminergic axons in the rat brain. Neuroreport 2007; 18: 137–140.
Kitayama I, Nakamura S, Yaga T, Murase S, Nomura J, Kayahara T et al. Degeneration of locus coeruleus axons in stress-induced depression model. Brain Res Bull 1994; 35: 573–580.
Dunlop BW, Nemeroff CB . The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007; 64: 327–337.
Berger PA, Faull KF, Kilkowski J, Anderson PJ, Kraemer H, Davis KL et al. CSF monoamine metabolites in depression and schizophrenia. Am J Psychiatry 1980; 137: 174–180.
Lambert G, Johansson M, Agren H, Friberg P . Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Arch Gen Psychiatry 2000; 57: 787–793.
Bremner JD, Vythilingam M, Ng CK, Vermetten E, Nazeer A, Oren DA et al. Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression. JAMA 2003; 289: 3125–3134.
Oswald LM, Wong DF, McCaul M, Zhou Y, Kuwabara H, Choi L et al. Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. Neuropsychopharmacology 2005; 30: 821–832.
Maes M, Bosmans E, Suy E, Vandervorst C, De Jonckheere C, Raus J . Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiology 1990; 24: 115–120.
Maes M . Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 664–675.
Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446–457.
Howren MB, Lamkin DM, Suls J . Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009; 71: 171–186.
Liu Y, Ho RC, Mak A . Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord 2011; PMID: 21872339.
Leonard BE, Maes M . Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012; 36: 764–785.
Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J . Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett 2011; 32: 7–24.
Celik C, Erdem M, Cayci T, Ozdemir B, Ozgur Akgul E, Kurt YG et al. The association between serum levels of neopterin and number of depressive episodes of major depression. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 372–375.
Maes M, Mihaylova I, Kubera M, Ringel K . Activation of cell-mediated immunity in depression: Association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression. Prog Neuropsychopharmacol Biol Psychiatry 2012; 36: 169–175.
Maes M, Ombelet W, De Jongh R, Kenis G, Bosmans E . The inflammatory response following delivery is amplified in women who previously suffered from major depression, suggesting that major depression is accompanied by a sensitization of the inflammatory response system. J Affect Disord 2001; 63: 85–92.
Hennessy MB, Paik KD, Caraway JD, Schiml PA, Deak T . Proinflammatory activity and the sensitization of depressive-like behavior during maternal separation. Behav Neurosci 2011; 125: 426–433.
Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009; 24: 27–53.
Bate C, Kempster S, Last V, Williams A . Interferon-gamma increases neuronal death in response to amyloid-beta1-42. J Neuroinflammation 2006; 3: 7.
Lambertsen KL, Gregersen R, Meldgaard M, Clausen BH, Heibol EK, Ladeby R et al. A role for interferon-gamma in focal cerebral ischemia in mice. J Neuropathol Exp Neurol 2004; 63: 942–955.
Hanisch UK, Neuhaus J, Rowe W, Van Rossum D, Moller T, Kettenmann H et al. Neurotoxic consequences of central long-term administration of interleukin-2 in rats. Neuroscience 1997; 79: 799–818.
Ye JH, Tao L, Zalcman SS . Interleukin-2 modulates N-methyl-D-aspartate receptors of native mesolimbic neurons. Brain Res 2001; 894: 241–248.
Viviani B, Gardoni F, Bartesaghi S, Corsini E, Facchi A, Galli CL et al. Interleukin-1 beta released by gp120 drives neural death through tyrosine phosphorylation and trafficking of NMDA receptors. J Biol Chem 2006; 281: 30212–30222.
Patel HC, Ross FM, Heenan LE, Davies RE, Rothwell NJ, Allan SM . Neurodegenerative actions of interleukin-1 in the rat brain are mediated through increases in seizure activity. J Neurosci Res 2006; 83: 385–391.
Pinteaux E, Trotter P, Simi A . Cell-specific and concentration-dependent actions of interleukin-1 in acute brain inflammation. Cytokine 2009; 45: 1–7.
Thornton P, Pinteaux E, Gibson RM, Allan SM, Rothwell NJ . Interleukin-1-induced neurotoxicity is mediated by glia and requires caspase activation and free radical release. J Neurochem 2006; 98: 258–266.
Thornton P, Pinteaux E, Allan SM, Rothwell NJ . Matrix metalloproteinase-9 and urokinase plasminogen activator mediate interleukin-1-induced neurotoxicity. Mol Cell Neurosci 2008; 37: 135–142.
Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T et al. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry 2008; 13: 717–728.
Koo JW, Duman RS . IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci USA 2008; 105: 751–756.
Song C, Wang H . Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 760–768.
Zou JY, Crews FT . TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res 2005; 1034: 11–24.
Murr C, Fuchs D, Gossler W, Hausen A, Reibnegger G, Werner ER et al. Enhancement of hydrogen peroxide-induced luminol-dependent chemiluminescence by neopterin depends on the presence of iron chelator complexes. FEBS Lett 1994; 338: 223–226.
Weiss G, Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G et al. Neopterin modulates toxicity mediated by reactive oxygen and chloride species. FEBS Lett 1993; 321: 89–92.
Schobersberger W, Hoffmann G, Hobisch-Hagen P, Bock G, Volkl H, Baier-Bitterlich G et al. Neopterin and 7,8-dihydroneopterin induce apoptosis in the rat alveolar epithelial cell line L2. FEBS Lett 1996; 397: 263–268.
Maes M, Galecki P, Chang YS, Berk M . A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 676–692.
Baier-Bitterlich G, Fuchs D, Murr C, Reibnegger G, Werner-Felmayer G, Sgonc R et al. Effect of neopterin and 7,8-dihydroneopterin on tumor necrosis factor-alpha induced programmed cell death. FEBS Lett 1995; 364: 234–238.
Swaab DF, Bao AM, Lucassen PJ . The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev 2005; 4: 141–194.
Holsboer F, Spengler D, Heuser I . The role of corticotropin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorders and dementia. Prog Brain Res 1992; 93: 385–417.
Nemeroff CB, Vale WW . The neurobiology of depression: inroads to treatment and new drug discovery. J Clin Psychiatry 2005; 66 (Suppl 7): 5–13.
Pariante CM, Lightman SL . The HPA axis in major depression: classical theories and new developments. Trends Neurosci 2008; 31: 464–468.
De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M . Glucocorticoid feedback resistance. Trends Endocrinol Metab 1997; 8: 26–33.
Pariante CM . Glucocorticoid receptor function in vitro in patients with major depression. Stress 2004; 7: 209–219.
Anacker C, Zunszain PA, Cattaneo A, Carvalho LA, Garabedian MJ, Thuret S et al. Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor. Mol Psychiatry 2011; 16: 738–750.
Cassidy EM, O’Keane V . Depression and interferon-alpha therapy. Br J Psychiatry J Mental Sci 2000; 176: 494.
Raison CL, Capuron L, Miller AH . Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006; 27: 24–31.
Maes M, Scharpe S, Meltzer HY, Bosmans E, Suy E, Calabrese J et al. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res 1993; 49: 11–27.
Maes M, Bosmans E, Suy E, Vandervorst C, DeJonckheere C, Raus J . Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiatr Scand 1991; 84: 379–386.
Zunszain PA, Anacker C, Cattaneo A, Carvalho LA, Pariante CM . Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 722–729.
Perlman WR, Webster MJ, Kleinman JE, Weickert CS . Reduced glucocorticoid and estrogen receptor alpha messenger ribonucleic acid levels in the amygdala of patients with major mental illness. Biol Psychiatry 2004; 56: 844–852.
Webster MJ, Knable MB, O’Grady J, Orthmann J, Weickert CS . Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol Psychiatry 2002; 7: 985–994, 924.
Szczepankiewicz A, Leszczynska-Rodziewicz A, Pawlak J, Rajewska-Rager A, Dmitrzak-Weglarz M, Wilkosc M et al. Glucocorticoid receptor polymorphism is associated with major depression and predominance of depression in the course of bipolar disorder. J Affect Disord 2011; 134: 138–144.
Zimmermann P, Bruckl T, Nocon A, Pfister H, Binder EB, Uhr M et al. Interaction of FKBP5 gene variants and adverse life events in predicting depression onset: results from a 10-Year prospective community study. Am J Psychiatry 2011; 168: 1107–1116.
Jaaskelainen T, Makkonen H, Palvimo JJ . Steroid up-regulation of FKBP51 and its role in hormone signaling. Curr Opin Pharmacol 2011; 11: 326–331.
Binder EB . The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 2009; 34 (Suppl 1): S186–S195.
Maes M, Mihaylova I, Kubera M, Leunis JC, Geffard M . IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: New pathways that underpin the inflammatory and neuroprogressive pathophysiology. J Affect Disord 2011; 135: 414–418.
Arlt S, Kontush A, Muller-Thomsen T, Beisiegel U . Lipid peroxidation as a common pathomechanism in coronary heart disease and Alzheimer disease]. Z Gerontol Geriatr 2001; 34: 461–465.
Sultana R, Perluigi M, Butterfield DA . Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: insights into mechanism of neurodegeneration from redox proteomics. Antioxid Redox Signal 2006; 8: 2021–2037.
Greilberger J, Koidl C, Greilberger M, Lamprecht M, Schroecksnadel K, Leblhuber F et al. Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease. Free Radic Res 2008; 42: 633–638.
Gorina R, Sanfeliu C, Galito A, Messeguer A, Planas AM . Exposure of glia to pro-oxidant agents revealed selective Stat1 activation by H2O2 and Jak2-independent antioxidant features of the Jak2 inhibitor AG490. Glia 2007; 55: 1313–1324.
Vanlangenakker N, Vanden Berghe T, Krysko DV, Festjens N, Vandenabeele P . Molecular mechanisms and pathophysiology of necrotic cell death. Curr Mol Med 2008; 8: 207–220.
Haorah J, Ramirez SH, Floreani N, Gorantla S, Morsey B, Persidsky Y . Mechanism of alcohol-induced oxidative stress and neuronal injury. Free Radic Biol Med 2008; 45: 1542–1550.
Feng Z, Hu W, Marnett LJ, Tang MS . Malondialdehyde, a major endogenous lipid peroxidation product, sensitizes human cells to UV- and BPDE-induced killing and mutagenesis through inhibition of nucleotide excision repair. Mutat Res 2006; 601: 125–136.
Long J, Wang X, Gao H, Liu Z, Liu C, Miao M et al. Malonaldehyde acts as a mitochondrial toxin: inhibitory effects on respiratory function and enzyme activities in isolated rat liver mitochondria. Life Sci 2006; 79: 1466–1472.
Poli G, Schaur RJ . 4-Hydroxynonenal in the pathomechanisms of oxidative stress. IUBMB Life 2000; 50: 315–321.
Akude E, Zherebitskaya E, Roy Chowdhury SK, Girling K, Fernyhough P . 4-Hydroxy-2-nonenal induces mitochondrial dysfunction and aberrant axonal outgrowth in adult sensory neurons that mimics features of diabetic neuropathy. Neurotox Res 2010; 17: 28–38.
Blanc EM, Keller JN, Fernandez S, Mattson MP . 4-hydroxynonenal, a lipid peroxidation product, impairs glutamate transport in cortical astrocytes. Glia 1998; 22: 149–160.
Lovell MA, Markesbery WR . Amyloid beta peptide, 4-hydroxynonenal and apoptosis. Curr Alzheimer Res 2006; 3: 359–364.
Picklo MJ, Amarnath V, McIntyre JO, Graham DG, Montine TJ . 4-Hydroxy-2(E)-nonenal inhibits CNS mitochondrial respiration at multiple sites. J Neurochem 1999; 72: 1617–1624.
Burridge S . Myristic acid: linkage of this saturated fatty acid to a wide variety of proteins has a key role in processes such as protein membrane localization and ceramide biosynthesis. Lipidomics Gateway. Nature Publishing Group, 2011; 9500 Gilman Drive, MC 0601 La Jolla, CA 92093-0601.
Lowy DR, Willumsen BM . Function and regulation of ras. Annu Rev Biochem 1993; 62: 851–891.
Zhang Z, Lee YC, Kim SJ, Choi MS, Tsai PC, Xu Y et al. Palmitoyl-protein thioesterase-1 deficiency mediates the activation of the unfolded protein response and neuronal apoptosis in INCL. Hum Mol Genet 2006; 15: 337–346.
Dhir A, Kulkarni SK . Nitric oxide and major depression. Nitric Oxide 2011; 24: 125–131.
Suzuki E, Yagi G, Nakaki T, Kanba S, Asai M . Elevated plasma nitrate levels in depressive states. J Affect Disord 2001; 63: 221–224.
Lee BH, Lee SW, Yoon D, Lee HJ, Yang JC, Shim SH et al. Increased plasma nitric oxide metabolites in suicide attempters. Neuropsychobiology 2006; 53: 127–132.
Joca SR, Guimaraes FS . Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects. Psychopharmacology (Berl) 2006; 185: 298–305.
Dhir A, Kulkarni SK . Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. Eur J Pharmacol 2007; 568: 177–185.
Kumar A, Garg R, Gaur V, Kumar P . Nitric oxide modulation in protective role of antidepressants against chronic fatigue syndrome in mice. Indian J Pharmacol 2011; 43: 324–329.
Seilicovich A, Lasaga M, Befumo M, Duvilanski BH, del Carmen Diaz M, Rettori V et al. Nitric oxide inhibits the release of norepinephrine and dopamine from the medial basal hypothalamus of the rat. Proc Natl Acad Sci USA 1995; 92: 11299–11302.
Kaye DM, Wiviott SD, Kobzik L, Kelly RA, Smith TW . S-nitrosothiols inhibit neuronal norepinephrine transport. Am J Physiol 1997; 272 (2 Pt 2): H875–H883.
Karolewicz B, Paul IA, Antkiewicz-Michaluk L . Effect of NOS inhibitor on forced swim test and neurotransmitters turnover in the mouse brain. Pol J Pharmacol 2001; 53: 587–596.
Zhang J, Huang XY, Ye ML, Luo CX, Wu HY, Hu Y et al. Neuronal nitric oxide synthase alteration accounts for the role of 5-HT1A receptor in modulating anxiety-related behaviors. J Neurosci 2010; 30: 2433–2441.
Crespi F . The selective serotonin reuptake inhibitor fluoxetine reduces striatal in vivo levels of voltammetric nitric oxide (NO): a feature of its antidepressant activity? Neurosci Lett 2010; 470: 95–99.
Kaster MP, Ferreira PK, Santos AR, Rodrigues AL . Effects of potassium channel inhibitors in the forced swimming test: possible involvement of L-arginine-nitric oxide-soluble guanylate cyclase pathway. Behav Brain Res 2005; 165: 204–209.
Wong ML, Whelan F, Deloukas P, Whittaker P, Delgado M, Cantor RM et al. Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc Natl Acad Sci USA 2006; 103: 15124–15129.
Leon J, Escames G, Rodriguez MI, Lopez LC, Tapias V, Entrena A et al. Inhibition of neuronal nitric oxide synthase activity by N1-acetyl-5-methoxykynuramine, a brain metabolite of melatonin. J Neurochem 2006; 98: 2023–2033.
De Berardis D, Di Iorio G, Acciavatti T, Conti C, Serroni N, Olivieri L et al. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurol Disord Drug Targets 2011; 10: 119–132.
Baxter Jr LR, Phelps ME, Mazziotta JC, Schwartz JM, Gerner RH, Selin CE et al. Cerebral metabolic rates for glucose in mood disorders. Studies with positron emission tomography and fluorodeoxyglucose F 18. Arch Gen Psychiatry 1985; 42: 441–447.
Gardner A, Johansson A, Wibom R, Nennesmo I, von Dobeln U, Hagenfeldt L et al. Alterations of mitochondrial function and correlations with personality traits in selected major depressive disorder patients. J Affect Disord 2003; 76: 55–68.
Gardner A, Pagani M, Wibom R, Nennesmo I, Jacobsson H, Hallstrom T . Alterations of rCBF and mitochondrial dysfunction in major depressive disorder: a case report. Acta Psychiatr Scand 2003; 107: 233–239.
Gardner A, Boles RG . Symptoms of somatization as a rapid screening tool for mitochondrial dysfunction in depression. Biopsychosoc Med 2008; 2: 7.
Gardner A, Boles RG . Mitochondrial energy depletion in depression with somatization. Psychother Psychosom 2008; 77: 127–129.
Burnett BB, Gardner A, Boles RG . Mitochondrial inheritance in depression, dysmotility and migraine? J Affect Disord 2005; 88: 109–116.
Voloboueva LA, Giffard RG . Inflammation, mitochondria, and the inhibition of adult neurogenesis. J Neurosci Res 2011; 89: 1989–1996.
Gong Y, Chai Y, Ding JH, Sun XL, Hu G . Chronic mild stress damages mitochondrial ultrastructure and function in mouse brain. Neurosci Lett 2011; 488: 76–80.
Gardner A, Boles RG . Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 730–743.
Scaini G, Maggi DD, De-Nês BT, Gonçalves CL, Ferreira GK, Teodorak BP et al. Activity of mitochondrial respiratory chain is increased by chronic administration of antidepressants. Acta Neuropsychiatrica 2011; 23: 112–118.
Kirby DM, Rennie KJ, Smulders-Srinivasan TK, Acin-Perez R, Whittington M, Enriquez JA et al. Transmitochondrial embryonic stem cells containing pathogenic mtDNA mutations are compromised in neuronal differentiation. Cell Prolif 2009; 42: 413–424.
Zell R, Geck P, Werdan K, Boekstegers P . TNF-alpha and IL-1 alpha inhibit both pyruvate dehydrogenase activity and mitochondrial function in cardiomyocytes: evidence for primary impairment of mitochondrial function. Mol Cell Biochem 1997; 177: 61–67.
Samavati L, Lee I, Mathes I, Lottspeich F, Huttemann M . Tumor necrosis factor alpha inhibits oxidative phosphorylation through tyrosine phosphorylation at subunit I of cytochrome c oxidase. J Biol Chem 2008; 283: 21134–21144.
Petrozzi L, Ricci G, Giglioli NJ, Siciliano G, Mancuso M . Mitochondria and neurodegeneration. Biosci Rep 2007; 27: 87–104.
Lin MT, Beal MF . Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443: 787–795.
Mancuso C, Scapagini G, Curro D, Giuffrida Stella AM, De Marco C, Butterfield DA et al. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front Biosci 2007; 12: 1107–1123.
Hanson ND, Owens MJ, Nemeroff CB . Depression, antidepressants, and neurogenesis: a critical reappraisal. Neuropsychopharmacology 2011; 36: 2589–2602.
Cameron HA, McKay RD . Adult neurogenesis produces a large pool of new granule cells in the dentate gyrus. J Comp Neurol 2001; 435: 406–417.
Bocchio-Chiavetto L, Bagnardi V, Zanardini R, Molteni R, Nielsen MG, Placentino A et al. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry 2010; 11: 763–773.
Viikki M, Anttila S, Kampman O, Illi A, Huuhka M, Setala-Soikkeli E et al. Vascular endothelial growth factor (VEGF) polymorphism is associated with treatment resistant depression. Neurosci Lett 2010; 477: 105–108.
Feily A, Namazi MR . Decrease of insulin growth factor-1 as a novel mechanism for anti-androgen effect of isotretinoin and its reported association with depression in some cases. J Drugs Dermatol 2011; 10: 793–794.
First M, Gil-Ad I, Taler M, Tarasenko I, Novak N, Weizman A . The effects of fluoxetine treatment in a chronic mild stress rat model on depression-related behavior, brain neurotrophins and ERK expression. J Mol Neurosci 2011; 45: 246–255.
Mallei A, Shi B, Mocchetti I . Antidepressant treatments induce the expression of basic fibroblast growth factor in cortical and hippocampal neurons. Mol Pharmacol 2002; 61: 1017–1024.
Yang K, Xie GR, Hu YQ, Mao FQ, Su LY . The effects of gender and numbers of depressive episodes on serum S100B levels in patients with major depression. J Neural Transm 2008; 115: 1687–1694.
Hisaoka K, Takebayashi M, Tsuchioka M, Maeda N, Nakata Y, Yamawaki S . Antidepressants increase glial cell line-derived neurotrophic factor production through monoamine-independent activation of protein tyrosine kinase and extracellular signal-regulated kinase in glial cells. J Pharmacol Exp Ther 2007; 321: 148–157.
Hoshaw BA, Malberg JE, Lucki I . Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res 2005; 1037: 204–208.
Turner CA, Gula EL, Taylor LP, Watson SJ, Akil H . Antidepressant-like effects of intracerebroventricular FGF2 in rats. Brain Res 2008; 1224: 63–68.
Allaman I, Fiumelli H, Magistretti PJ, Martin JL . Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes. Psychopharmacology (Berl) 2011; 216: 75–84.
Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003; 54: 70–75.
Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM . Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002; 109: 143–148.
Lee BH, Kim H, Park SH, Kim YK . Decreased plasma BDNF level in depressive patients. J Affect Disord 2007; 101: 239–244.
Molendijk ML, Bus BA, Spinhoven P, Penninx BW, Kenis G, Prickaerts J et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 2011; 16: 1088–1095.
Roth TL, Sweatt JD . Epigenetic marking of the BDNF gene by early-life adverse experiences. Horm Behav 2011; 59: 315–320.
Roth TL, Lubin FD, Funk AJ, Sweatt JD . Lasting epigenetic influence of early-life adversity on the BDNF gene. Biol Psychiatry 2009; 65: 760–769.
Gomez-Pinilla F, Vaynman S . A ‘deficient environment’ in prenatal life may compromise systems important for cognitive function by affecting BDNF in the hippocampus. Exp Neurol 2005; 192: 235–243.
Yu H, Chen ZY . The role of BDNF in depression on the basis of its location in the neural circuitry. Acta Pharmacol Sin 2011; 32: 3–11.
Eker C, Kitis O, Taneli F, Eker OD, Ozan E, Yucel K et al. Correlation of serum BDNF levels with hippocampal volumes in first episode, medication-free depressed patients. Eur Arch Psychiatry Clin Neurosci 2010; 260: 527–533.
Donato R, Sorci G, Riuzzi F, Arcuri C, Bianchi R, Brozzi F et al. S100B's double life: intracellular regulator and extracellular signal. Biochim Biophys Acta 2009; 1793: 1008–1022.
Uddin M, Koenen KC, Aiello AE, Wildman DE, de los Santos R, Galea S . Epigenetic and inflammatory marker profiles associated with depression in a community-based epidemiologic sample. Psychol Med 2011; 41: 997–1007.
Weaver IC, Cervoni N, Champagne FA, D’Alessio AC, Sharma S, Seckl JR et al. Epigenetic programming by maternal behavior. Nat Neurosci 2004; 7: 847–854.
Weaver IC, Champagne FA, Brown SE, Dymov S, Sharma S, Meaney MJ et al. Reversal of maternal programming of stress responses in adult offspring through methyl supplementation: altering epigenetic marking later in life. J Neurosci 2005; 25: 11045–11054.
Kinnally EL, Capitanio JP, Leibel R, Deng L, LeDuc C, Haghighi F et al. Epigenetic regulation of serotonin transporter expression and behavior in infant rhesus macaques. Genes Brain Behav 2010; 9: 575–582.
Melas PA, Rogdaki M, Lennartsson A, Bjork K, Qi H, Witasp A et al. Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression. Int J Neuropsychopharmacol 2011; 1–11; PMID: 21682946.
Guo JU, Ma DK, Mo H, Ball MP, Jang MH, Bonaguidi MA et al. Neuronal activity modifies the DNA methylation landscape in the adult brain. Nat Neurosci 2011; 14: 1345–1351.
Russo-Neustadt AA, Alejandre H, Garcia C, Ivy AS, Chen MJ . Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise. Neuropsychopharmacology 2004; 29: 2189–2199.
Reagan LP, Hendry RM, Reznikov LR, Piroli GG, Wood GE, McEwen BS et al. Tianeptine increases brain-derived neurotrophic factor expression in the rat amygdala. Eur J Pharmacol 2007; 565: 68–75.
Vinet J, Carra S, Blom JM, Brunello N, Barden N, Tascedda F . Chronic treatment with desipramine and fluoxetine modulate BDNF, CaMKKalpha and CaMKKbeta mRNA levels in the hippocampus of transgenic mice expressing antisense RNA against the glucocorticoid receptor. Neuropharmacology 2004; 47: 1062–1069.
Rantamaki T, Hendolin P, Kankaanpaa A, Mijatovic J, Piepponen P, Domenici E et al. Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain. Neuropsychopharmacology 2007; 32: 2152–2162.
Rantamaki T, Vesa L, Antila H, Di Lieto A, Tammela P, Schmitt A et al. Antidepressant drugs transactivate TrkB neurotrophin receptors in the adult rodent brain independently of BDNF and monoamine transporter blockade. PLoS One 2011; 6: e20567.
Rantamaki T, Castren E . Targeting TrkB neurotrophin receptor to treat depression. Expert Opin Ther Targets 2008; 12: 705–715.
Cazorla M, Premont J, Mann A, Girard N, Kellendonk C, Rognan D . Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice. J Clin Invest 2011; 121: 1846–1857.
Cazorla M, Jouvenceau A, Rose C, Guilloux JP, Pilon C, Dranovsky A et al. Cyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in mice. PLoS One 2010; 5: e9777.
Sutcigil L, Oktenli C, Musabak U, Bozkurt A, Cansever A, Uzun O et al. Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol 2007; 2007: 76396.
Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E . Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 2003; 170: 429–433.
McNamee EN, Griffin EW, Ryan KM, Ryan KJ, Heffernan S, Harkin A et al. Noradrenaline acting at beta-adrenoceptors induces expression of IL-1beta and its negative regulators IL-1ra and IL-1RII, and drives an overall anti-inflammatory phenotype in rat cortex. Neuropharmacology 2010; 59: 37–48.
McNamee EN, Ryan KM, Griffin EW, Gonzalez-Reyes RE, Ryan KJ, Harkin A et al. Noradrenaline acting at central beta-adrenoceptors induces interleukin-10 and suppressor of cytokine signaling-3 expression in rat brain: implications for neurodegeneration. Brain Behav Immun 2010; 24: 660–671.
Reynolds JL, Ignatowski TA, Sud R, Spengler RN . An antidepressant mechanism of desipramine is to decrease tumor necrosis factor-alpha production culminating in increases in noradrenergic neurotransmission. Neuroscience 2005; 133: 519–531.
Hayley S . Toward an anti-inflammatory strategy for depression. Front Behav Neurosci 2011; 5: 19.
Galecki P, Szemraj J, Bienkiewicz M, Zboralski K, Galecka E . Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum Psychopharmacol 2009; 24: 277–286.
Brunello N, Alboni S, Capone G, Benatti C, Blom JM, Tascedda F et al. Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. Int Clin Psychopharmacol 2006; 21: 219–225.
Mendlewicz J, Kriwin P, Oswald P, Souery D, Alboni S, Brunello N . Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int Clin Psychopharmacol 2006; 21: 227–231.
Wang Y, Yang F, Liu YF, Gao F, Jiang W . Acetylsalicylic acid as an augmentation agent in fluoxetine treatment resistant depressive rats. Neurosci Lett 2011; 499: 74–79.
Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006; 11: 680–684.
Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009; 26: 607–611.
Dunston CR, Griffiths HR, Lambert PA, Staddon S, Vernallis AB . Proteomic analysis of the anti-inflammatory action of minocycline. Proteomics 2011; 11: 42–51.
Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, Olivera-Lopez JI, Jaramillo-Jaimes MT . Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 380–386.
Pae CU, Marks DM, Han C, Patkar AA . Does minocycline have antidepressant effect? Biomed Pharmacother 2008; 62: 308–311.
Miskowiak KW, Vinberg M, Harmer CJ, Ehrenreich H, Kessing LV . Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression. Psychopharmacology (Berl) 2012; 219: 687–698.
Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29–35.
Maas DW, Westendorp RG, Willems JM, de Craen AJ, van der Mast RC . TNF-alpha antagonist infliximab in the treatment of depression in older adults: results of a prematurely ended, randomized, placebo-controlled trial. J Clin Psychopharmacol 2010; 30: 343–345.
Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26: 643–652.
Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M . Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 2002; 72: 237–241.
Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344: 961–966.
Sicard P, Delemasure S, Korandji C, Segueira-Le Grand A, Lauzier B, Guilland JC et al. Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats. Free Radic Res 2008; 42: 226–236.
Gomez-Garcia A, Martinez Torres G, Ortega-Pierres LE, Rodriguez-Ayala E, Alvarez-Aguilar C . Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia]. Rev Esp Cardiol 2007; 60: 1242–1249.
Link A, Ayadhi T, Bohm M, Nickenig G . Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur Heart J 2006; 27: 2945–2955.
Schupp N, Schmid U, Heidland A, Stopper H . Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis. Atherosclerosis 2008; 199: 278–287.
Holvoet P . Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh K Acad Geneeskd Belg 2008; 70: 193–219.
Young-Xu Y, Chan KA, Liao JK, Ravid S, Blatt CM . Long-term statin use and psychological well-being. J Am Coll Cardiol 2003; 42: 690–697.
Stafford L, Berk M . The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: proof of concept for the inflammatory and oxidative hypotheses of depression? J Clin Psychiatry 2011; 72: 1229–1235.
Pasco JA, Jacka FN, Williams LJ, Henry MJ, Nicholson GC, Kotowicz MA et al. Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression. Psychother Psychosom 2010; 79: 323–325.
Jacka FN, Pasco JA, Mykletun A, Williams LJ, Hodge AM . Association of western and traditional diets with depression and anxiety in women. Am J Psychiatry 2010; 167: 305–311.
Krolow R, Noschang CG, Arcego D, Andreazza AC, Peres W, Goncalves CA et al. Consumption of a palatable diet by chronically stressed rats prevents effects on anxiety-like behavior but increases oxidative stress in a sex-specific manner. Appetite 2010; 55: 108–116.
DeMar Jr JC, Ma K, Bell JM, Igarashi M, Greenstein D, Rapoport SI . One generation of n-3 polyunsaturated fatty acid deprivation increases depression and aggression test scores in rats. J Lipid Res 2006; 47: 172–180.
Huang SY, Yang HT, Chiu CC, Pariante CM, Su KP . Omega-3 fatty acids on the forced-swimming test. J Psychiatr Res 2008; 42: 58–63.
Venna VR, Deplanque D, Allet C, Belarbi K, Hamdane M, Bordet R . PUFA induce antidepressant-like effects in parallel to structural and molecular changes in the hippocampus. Psychoneuroendocrinology 2009; 34: 199–211.
Ferraz AC, Delattre AM, Almendra RG, Sonagli M, Borges C, Araujo P et al. Chronic omega-3 fatty acids supplementation promotes beneficial effects on anxiety, cognitive and depressive-like behaviors in rats subjected to a restraint stress protocol. Behav Brain Res 2011; 219: 116–122.
Lu DY, Tsao YY, Leung YM, Su KP . Docosahexaenoic acid suppresses neuroinflammatory responses and induces heme oxygenase-1 expression in BV-2 microglia: implications of antidepressant effects for omega-3 fatty acids. Neuropsychopharmacology 2010; 35: 2238–2248.
Song C, Zhang XY, Manku M . Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment. J Neurosci 2009; 29: 14–22.
Weaver KL, Ivester P, Seeds M, Case LD, Arm JP, Chilton FH . Effect of dietary fatty acids on inflammatory gene expression in healthy humans. J Biol Chem 2009; 284: 15400–15407.
Conklin SM, Gianaros PJ, Brown SM, Yao JK, Hariri AR, Manuck SB et al. Long-chain omega-3 fatty acid intake is associated positively with corticolimbic gray matter volume in healthy adults. Neurosci Lett 2007; 421: 209–212.
McNamara RK . DHA deficiency and prefrontal cortex neuropathology in recurrent affective disorders. J Nutr 2010; 140: 864–868.
Appleton KM, Rogers PJ, Ness AR . Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr 2010; 91: 757–770.
Lin PY, Su KP . A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 2007; 68: 1056–1061.
Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I et al. N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008; 64: 468–475.
Ferreira FR, Biojone C, Joca SR, Guimaraes FS . Antidepressant-like effects of N-acetyl-L-cysteine in rats. Behav Pharmacol 2008; 19: 747–750.
Dodd S, Dean O, Copolov DL, Malhi GS, Berk M . N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther 2008; 8: 1955–1962.
Qian HR, Yang Y . Neuron differentiation and neuritogenesis stimulated by N-acetylcysteine (NAC). Acta Pharmacol Sin 2009; 30: 907–912.
Dean OM, van den Buuse M, Bush AI, Copolov DL, Ng F, Dodd S et al. A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. Curr Med Chem 2009; 16: 2965–2976.
Satoh T, Ishige K, Sagara Y . Protective effects on neuronal cells of mouse afforded by ebselen against oxidative stress at multiple steps. Neurosci Lett 2004; 371: 1–5.
Muller A, Cadenas E, Graf P, Sies H . A novel biologically active seleno-organic compound—I. Glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ 51 (Ebselen). Biochem Pharmacol 1984; 33: 3235–3239.
Posser T, Kaster MP, Barauna SC, Rocha JB, Rodrigues AL, Leal RB . Antidepressant-like effect of the organoselenium compound ebselen in mice: evidence for the involvement of the monoaminergic system. Eur J Pharmacol 2009; 602: 85–91.
Lee YJ, Choi B, Lee EH, Choi KS, Sohn S . Immobilization stress induces cell death through production of reactive oxygen species in the mouse cerebral cortex. Neurosci Lett 2006; 392: 27–31.
The authors wish to gratefully acknowledge the assistance of Dr Harris Eyre in the preparation of this manuscript.
All authors are responsible for the design, content and research used in this manuscript. All authors have approved all manuscript contents.
Dr S Moylan, Professor NR Wray and Professor M Maes declare no conflict of interest. Professor M Berk has received Grant/Research Support from Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma and Servier, has been a speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvayand Wyeth, and served as a consultant to Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck and Servier.
About this article
Cite this article
Moylan, S., Maes, M., Wray, N. et al. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 18, 595–606 (2013). https://doi.org/10.1038/mp.2012.33
- nitrosative stress
- oxidative stress
Antidepressant Effect and Modulation of the Redox System Mediated by Tannic Acid on Lipopolysaccharide-Induced Depressive and Inflammatory Changes in Mice
Neurochemical Research (2020)
Increased Serum Immunoglobulin Responses to Gut Commensal Gram-Negative Bacteria in Unipolar Major Depression and Bipolar Disorder Type 1, Especially When Melancholia Is Present
Neurotoxicity Research (2020)
Ageing Research Reviews (2020)
Proteomic analysis reveals a biosignature of decreased synaptic protein in cerebrospinal fluid of major depressive disorder
Translational Psychiatry (2020)
Duration of untreated eating disorder and relationship to outcomes: A systematic review of the literature
European Eating Disorders Review (2020)